Tumor necrosis factor alpha (TNF α) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles ...

Tumour necrosis factor (TNF) inhibitors have changed the therapeutic standard of treatment for patients with rheumatoid arthritis (RA), providing substantial benefits in terms of clinical and ...

The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis ... clinical trials that have assessed the use of TNF inhibitors in patients with AS, and briefly outlines ...

Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid arthritis (RA) are unfounded, at least for U.S. military veterans ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells in vitro, but its physiological role in tumor surveillance remains unknown. Here ...

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.